DrugPatentWatch Database Preview

Details for Patent: 8,795,725

« Back to Dashboard

Which drugs does patent 8,795,725 protect, and when does it expire?

Patent 8,795,725 protects HORIZANT and is included in one NDA.

This patent has twenty-three patent family members in sixteen countries.

Summary for Patent: 8,795,725

Title:	GABA analog prodrug sustained release oral dosage forms
Abstract:	Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
Inventor(s):	Cundy; Kenneth C. (Redwood City, CA), Sastry; Srikonda (Sunnyvale, CA), Leung; Manshiu (Daily City, CA), Kadri; Balaji V. (Tampa, FL), Stach; Paul E. (Plymouth, MN)
Assignee:	XenoPort, Inc. (Santa Clara, CA)
Application Number:	11/269,045
Patent Claim Types: see list of patent claims	Compound; Dosage form; Composition; Use;

Drugs Protected by US Patent 8,795,725

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Arbor Pharms Llc	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-002	Dec 13, 2011		RX	Yes	No			Y			MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
Arbor Pharms Llc	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-002	Dec 13, 2011		RX	Yes	No			Y			TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
Arbor Pharms Llc	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-001	Apr 6, 2011		RX	Yes	Yes			Y			MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
Arbor Pharms Llc	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-001	Apr 6, 2011		RX	Yes	Yes			Y			TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

Non-Orange Book US Patents Family Members for Patent 8,795,725

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,906,412	GABA analog prodrug sustained release oral dosage forms

International Patents Family Members for US Patent 8,795,725

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005301970
Brazil	PI0517227
Canada	2584338
China	101068538